The PIONEER trial program compared oral semaglutide with a number of interventions for type 2 diabetes, including empagliflozin 25 mg (PIONEER 2), sitagliptin 100 mg (PIONEER 3), and liraglutide 1.8 mg (PIONEER 4) [9,10,11,12]
All these factors are significantly involved in the pathophysiology of multiple obesity-related complications, including diabetes mellitus, metabolic dysfunction-associated steatotic liver disease, heart failure, and atherosclerosis, among others
GLP-1 receptor agonists are injectable or oral medications initially approved to treat type 2 diabetes
Niacinamide-containing formulations and L-carnitine blends represent newer approaches to improving stability and adding complementary benefits
A subgroup of the PCOS-induced mice received liraglutide 0.2 mg/kg for 21 consecutive days (twice daily, s.c.), while the other subgroup was treated with saline injections twice daily